Company Profile

Kineta Inc (AKA: Lecura, Inc~Kineta One LLC)
Profile last edited on: 12/2/2023      CAGE: 50NT6      UEI: NSHPJSN74LP8

Business Identifier: Next-generation immunotherapies: therapeutics for use in autoimmune disease, viral disease, and chronic pain areas.
Year Founded
2007
First Award
2008
Latest Award
2020
Program Status
Active (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

219 Terry Avenue North Suite 300
Seattle, WA 98109
   (206) 378-0400
   info@kinetabio.com
   www.kinetabio.com
Location: Single
Congr. District: 07
County: King

Public Profile

Established by long-time experienced business partners having previously launched and grown to M&A the firm Illumigen Biosciences, Kineta - formerly dba Lecura, Inc. - is organized around developing leading edge therapeutics in autoimmune disease, viral disease and chronic pain areas. A particular area of focus ihas been the discovery and development of antiviral therapies and immune modulating drugs for treatment of RNA viruses to include hepatitis C, influenza, west nile virus, and common cold. Employing a business model anchored in a broad range of collaborative efforts, the firm offers ShK Analogs for treatment of multiple sclerosis and autoimmune diseases; and RIG-I Pathway, a molecular on/off switch that triggers the human body's immune defenses against virus infection. In December 2022, Kineta completed its (reverse) merger with Yumanity Therapeutics, a move that had the effect of also making Kineta a public company (NASDA:KA). The combined company began trading Monday on the Nasdaq under the symbol KA and retains the Kineta name and leadership structure. Kineta also initiated enrollment in an early-stage clinical trial testing a candidate immunotherapy alone or in combination with Merck’s Keytruda.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
10-14
Revenue Range
1M-1.5M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
NASDAQ : KA
IP Holdings
50-74

Awards Distribution by Agency

Key People / Management

  Rob Hedequist -- President and Chief Operating Officer

  Shawn P Iadonato -- CEO

  Charles L Magness -- Founder President & CEO

  Craig Philips -- President

  Michael Banks -- foremr Chief Financial Officer: retired

  Kristin Bedard -- Co-Founder Vice President Research & Development and Head of Virology

  Jacques Bouchy -- Senior Vice President Business Development and Corporate Communications

  William Cadwallader -- Senior Vice President, Corporate Development

  Molly Dorr -- Sr. Director of Human Resource

  Luke Fouke -- Vice President, Business Development

  Michael Gale -- Founder

  Pauline Kenny -- General Counsel

  Kurt Lustig -- Associate Director, Preclinical Operations and Translational Development

  Jose L Mercado

  Ken North -- Senior Vice President Corporate Developme

  Peter Probst

  Eric Tarcha -- EVP Research & Development